Literature DB >> 9043842

Prognostic value of plasma endothelin-1 in patients with chronic heart failure.

F Pousset1, R Isnard, P Lechat, H Kalotka, A Carayon, G Maistre, S Escolano, D Thomas, M Komajda.   

Abstract

AIMS: Endothelin-1 is a potent vasoconstrictive and multifunctional peptide. Elevated concentrations have been reported in congestive heart failure. We hypothesized that the level of endothelin-1 in plasma is a prognostic marker in congestive heart failure. METHODS AND
RESULTS: Plasma levels of endothelin-1 were measured by radioimmunoassay in 120 congestive heart failure patients with ischaemic or non-ischaemic cardiomyopathy (mean ejection fraction 28 +/- 11%, in New York Heart Association (NYHA) functional class I:21, class II 35, class III: 61, class IV: 3). During a median follow-up of 361 +/- 338 days, 14 cardiac deaths occurred. In the univariate Cox model, endothelin-1 was the most powerful prognostic marker among the variables tested (P = 0.0001). A multivariate model, including plasma atrial natriuretic peptide and noradrenaline, NYHA class, age, and echocardiographic left ventricular end-diastolic diameter index was highly predictive of mortality (P = 0.00008), but only endothelin-1 remained significantly associated with outcome (P = 0.02). Patients with plasma endothelin-1 > or = 5 pg. ml-1 had a higher mortality rate than those with endothelin-1 < 5 pg. ml-1 (21% vs 4%, P = 0.001).
CONCLUSION: Our results suggest that elevated endothelin-1 plasma levels are associated with a poor prognosis and routine plasma endothelin-1 determination provides important prognostic information in mild to moderate heart failure.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9043842     DOI: 10.1093/oxfordjournals.eurheartj.a015228

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  31 in total

Review 1.  Heart failure in 10 years time: focus on pharmacological treatment.

Authors:  J J V McMurray
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

Review 2.  Emerging therapies for heart failure: renal mechanisms and effects.

Authors:  Amir Kazory; Edward A Ross
Journal:  Heart Fail Rev       Date:  2012-01       Impact factor: 4.214

Review 3.  Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure.

Authors:  H Krum; R Denver; A Tzanidis; P Martin
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 4.  Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

5.  The role of the neurohormonal system in heart failure.

Authors:  M Komajda; F Pousset; R Isnard; P Lechat
Journal:  Heart       Date:  1998-06       Impact factor: 5.994

6.  Plasma atrial natriuretic peptide (proANP 31-67), B-type natriuretic peptide (Nt-proBNP) and endothelin-1 (ET-1) concentrations in dogs with chronic degenerative valvular disease (CDVD).

Authors:  D Piantedosi; L Cortese; A Di Loria; G Brignola; M Prisco; A Persechino; P Ciaramella
Journal:  Vet Res Commun       Date:  2009-09       Impact factor: 2.459

Review 7.  The role of endothelin receptor antagonists in the treatment of chronic heart failure.

Authors:  W Kiowski; G Sütsch
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

Review 8.  Endothelin receptor antagonists and cardiovascular diseases of aging.

Authors:  M P Love; J J McMurray
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

9.  Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population.

Authors:  T A McDonagh; A D Cunningham; C E Morrison; J J McMurray; I Ford; J J Morton; H J Dargie
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

Review 10.  Biomarkers in heart failure: a clinical review.

Authors:  J Paul Rocchiccioli; John J V McMurray; Anna F Dominiczak
Journal:  Heart Fail Rev       Date:  2008-12-03       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.